Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibodyto Human S. aureus Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis and of methicillin-resistant S. aureus.
IgG1 - kappa
The details of the immunogen for this antibody are not available.
Suitable for use in IP, IF, FuncS, FC, Neut, ELISA, ICC and most other immunological methods.
Tested positive against native S. aureus antigen.
Predicted N terminal
H chain: QVQLKESL chain: DIVMTQS
Purity >95% by SDS-PAGE.
Store at -20°C. Avoid multiple freeze/thaw cycles.
Humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.
S. aureus may occur as a commensal on skin; it also occurs in the nose frequently (in about a third of the population) and the throat less commonly; S. aureus can infect other tissues when barriers have been breached. S. aureus infections may spread through contact with pus from an infected wound, skin-to-skin contact with an infected person by producing hyaluronidase that destroys tissues, and contact with objects such as towels, sheets, clothing, or athletic equipment used by an infected person. Deeply penetrating S. aureus infections can be severe. ClfA is a 92 kDa surface protein identified from S. aureus. ClfA is responsible for the fibrinogen-dependent c1umping of bacteria.